⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770520 | 0.67 | — | — | |
| SCHEMBL13278651 | 0.59 | — | — | |
| SCHEMBL19288029 | 0.59 | — | — | |
| SCHEMBL13278640 | 0.59 | — | — | |
| SCHEMBL181649 | 0.59 | — | — | |
| N-Nitrosodimethylamine SCHEMBL686 | 0.56 | — | — | |
| SCHEMBL18455720 | 0.56 | — | — | |
| SCHEMBL120206 | 0.56 | — | — | |
| SCHEMBL6533304 | 0.56 | — | — | |
| SCHEMBL6057258 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3744 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11946050-B2 | Polynucleotide compositions and methods for gene expression regulations | APTAH BIO, INC. (US) | 2024-04-02 | — | — | US | claimed |
| WO-2023220744-A2 | SINGLE-STRANDED LOOP OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| US-20230257745-A1 | Circular siRNAs | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | claimed |
| WO-2022011214-A1 | CIRCULAR SIRNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-01-13 | — | — | WO | claimed |
| EP-3919619-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | Alnylam Pharmaceuticals, Inc. (US) | 2021-12-08 | — | — | EP | claimed |
| EP-1971690-B1 | TRANSLATIONAL DYSFUNCTION BASED THERAPEUTICS | TRANSLATIONAL THERAPEUTICS INC (US) | 2018-10-17 | — | — | EP | claimed |
| EP-3324980-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | Alnylam Pharmaceuticals, Inc. (US) | 2018-05-30 | — | — | EP | claimed |
| WO-2017015109-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-01-26 | — | — | WO | claimed |
| US-8575123-B2 | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2013-11-05 | — | — | US | claimed |
| US-20130236968-A1 | MULTIFUNCTIONAL COPOLYMERS FOR NUCLEIC ACID DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | US | claimed |
| EP-0978561-A1 | Antisense oligonucleotides for the inhibition of VEGF expression | Hoechst Marion Roussel Deutschland GmbH (DE) | 2000-02-09 | — | — | EP | claimed |
| EP-0928290-A4 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS INC (US) | 2000-01-19 | — | — | EP | claimed |
| US-6013639-A | MODIFYING END GROUPS; DIAGNOSIS, THERAPY CANCER, RESTENOSIS | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-01-11 | — | — | US | claimed |
| WO-1999060011-A1 | SECRETION OF TOXINS BY GRAM-NEGATIVE BACTERIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-11-25 | — | — | WO | claimed |
| EP-0928290-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1999-07-14 | — | — | EP | claimed |
| WO-1999025819-A2 | ANTISENSE OLIGONUCLEOTIDES AGAINST TENASCIN FOR TREATING VITILIGO | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-05-27 | — | — | WO | claimed |
| US-5898031-A | Oligoribonucleotides for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 1999-04-27 | — | — | US | claimed |
| WO-1997046570-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | claimed |
| EP-0726274-A2 | G-cap stabilized oligonucleotides | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-08-14 | — | — | EP | claimed |
| EP-0653439-A2 | Stabilized oligonucleotids and the use thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-05-17 | — | — | EP | claimed |